Multiple Myeloma Hereditary Risk — first-degree relatives have 2-4x increased risk, and genetic profiling of MGUS patients may help predict which individuals will progress to myeloma requiring treatment.
Whole genome sequencing evaluates all known myeloma susceptibility loci and germline variants — providing genetic risk assessment that may guide MGUS surveillance intensity and early myeloma detection strategies.
Multiple Myeloma — Hereditary
Multiple myeloma is a plasma cell malignancy affecting approximately 35,000 Americans annually. While most myeloma is sporadic, epidemiological studies consistently demonstrate familial clustering — first-degree relatives of myeloma patients have approximately 2-4x increased risk of developing myeloma and other lymphoproliferative disorders. Genome-wide association studies have identified multiple susceptibility loci including variants at 2p23.3, 3p22.1, 3q26.2, 6p21.33 (HLA region), 7p15.3, and 17p11.2, each conferring modest individual risk increases that compound in polygenic risk scores.
Monoclonal gammopathy of undetermined significance (MGUS) precedes virtually all myeloma cases, with approximately 1% of MGUS progressing to myeloma per year. The clinical challenge is identifying which MGUS patients will progress. Genetic risk profiling — combining germline susceptibility variants with MGUS-specific risk factors (M-protein level, immunoglobulin subtype, free light chain ratio) — represents an emerging approach to risk-stratified MGUS surveillance that could enable earlier myeloma detection at more treatable stages.
Familial myeloma kindreds have been described with multiple affected family members across generations, suggesting higher-penetrance germline variants in a subset of cases. Candidate genes under investigation include KDM1A, LSD1, and variants in DNA damage response pathways. Additionally, germline variants affecting immune function and B-cell biology may predispose to the immune dysregulation underlying MGUS and myeloma development. Comprehensive genomic evaluation through WGS enables ongoing reanalysis as myeloma genetics research matures.
MGUS precedes virtually all myeloma — it's the premalignant phase. Identifying individuals at highest genetic risk for MGUS progression could enable earlier myeloma detection when treatment is most effective.
Myeloma genetics is an actively evolving field. WGS provides a permanent genomic resource for ongoing reanalysis as new myeloma susceptibility genes and progression biomarkers are discovered.
First-degree relatives of myeloma patients have 2-4x increased risk — genetic evaluation supports risk-stratified screening
Family members of myeloma patients are at significantly elevated risk for both MGUS and myeloma. Serum protein electrophoresis (SPEP) screening can detect MGUS before myeloma develops. Genetic risk profiling through WGS can help identify which family members would benefit most from regular SPEP screening — focusing surveillance resources on those with the highest genetic predisposition.
Polygenic risk scores for myeloma are improving — WGS captures all known and emerging susceptibility variants
As myeloma GWAS studies expand and new susceptibility loci are discovered, polygenic risk scores will become increasingly predictive. WGS data captured today can be reanalyzed against future risk score models without requiring additional testing. This 'test once, analyze forever' approach is particularly valuable for evolving cancer genetics fields like myeloma.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Multiple Myeloma — Hereditary and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
